Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus

Journal of Investigative Medicine

Volumn 61, Issue 5, 2013, Pages 861-866

  Zhao, Peng ^a   Wu, Mingchun ^b   Yu, Houyou ^a   Huang, Yang ^a   Wang, Yutong ^a   Wang, Wei ^a   Yin, Wen ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

Author keywords

Biomarker; Coronary atherosclerosis index; S100A12; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ATHEROSCLEROSIS INDEX SCORE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; S100 PROTEINS;

EID: 84881507937     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318292fb1e     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003.
2. Versari D, Daghini E, Virdis A., et al Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009; 32(SUPPL. 2):S314-S321.
3. Pietzsch J, Hoppmann S. Human S100A12: a novel key player in inflammation? Amino Acids. 2009; 36:381-389.
4. Leach ST, Yang Z, Messina I., et al Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007; 42:1321-1331.
5. Foell D, Kane D, Bresnihan B., et al Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford). 2003; 42:1383-1389.
6. Komatsuda A, Ohtani H, Wakui H., et al Increased serum levels of S100A12 in patients with MPO-ANCAYassociated glomerulonephritis. Clin Nephrol. 2006; 66:315-321.
7. Kosaki A, Hasegawa T, Kimura T., et al Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004; 89:5423-5428.
8. Goyette J, Yan WX, Yamen E, et al Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol. 2009; 183:593-603.
9. Alberti KG, Zimmet PZ Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 1998; 15:539-553.
10. Tatami R, Mabuchi H, Ueda K., et al Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981; 64:1174-1184.
11. Haffner SM, Lehto S, Rönnemaa T, et al Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-234.
12. Calles-Escadon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev. 2001; 22:36-52.
13. Basta G, Sironi AM, Lazzerini G, et al Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006; 91:4628-4634.
14. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010; 59:249-255.
15. Abbas A, Aukrust P, Dahl T.B., et al High levels of S100A12 are associated with recent plaque symptomatology in patients with carotid atherosclerosis. Stroke. 2012; 43:1347-1353.
16. Mori Y, Kosaki A, Kishimoto N., et al Increased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclerosis. Am J Nephrol. 2009; 29:18-24.
17. Mahajan N, Malik N, Bahl A., et al Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 2009; 207:597-602.
18. Daugherty A, Rateri DL, Lu H. S100A12 links to thoracic aortic aneurysms. Circ Res. 2010; 106:13-15.
19. Alexiou P, Chatzopoulou M, Pegklidou K., et al RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr Med Chem. 2010; 17:2232-2252.
20. Brownlee M, Cerami A, Vlassara H. Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic vascular disease. Diabetes Metab Rev. 1988; 4:437-451.
21. Burke AP, Kolodgie FD, Zieske A, et al Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004; 24:1266-1271.
22. Saito T, Hojo Y, Ogoyama Y., et al S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circ J. 2012; 76:2647-2652.
23. Morrow DA, Wang Y, Croce K., et al Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008; 155:49-55.